Evaluate the hemolytic effect of Loureirin A on red blood cells, showing no hemolysis at 0-280 µM.
Life (Basel). 2025 Mar 3;15(3):396
Primary human dermal fibroblast cells
0-350 µM
24 and 48 hours
Evaluate the toxicity of Loureirin A on primary human dermal fibroblast cells, showing no toxicity at 0-350 µM.
Life (Basel). 2025 Mar 3;15(3):396
H1299 cells
0-140 µM
24 hours
Evaluate the effect of Loureirin A on the viability of H1299 cells, showing no toxicity at 0-140 µM.
Life (Basel). 2025 Mar 3;15(3):396
A549 cells
0-140 µM
24 hours
Evaluate the effect of Loureirin A on the viability of A549 cells, showing no toxicity at 0-140 µM.
Life (Basel). 2025 Mar 3;15(3):396
hair follicle stem cells
20 µg/ml
24 hours
To investigate the effect of Loureirin A on hair follicle stem cell differentiation, results showed that Loureirin A promoted HFSC differentiation by downregulating miR‑339‑5p.
Mol Med Rep. 2018 Aug;18(2):1279-1286
Various non-Helicobacter strains
32 µg/mL to >128 µg/mL
To evaluate the antimicrobial spectrum of LrA against various non-Helicobacter strains, results showed that LrA's activity against these strains was at least eight times higher than against H. pylori, indicating LrA is a narrow-spectrum anti-H. pylori molecule.
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0031424
Loureirin A/龙血素 A 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
H. pylori infection model
Oral gavage
28 mg/kg
Once daily for 4 consecutive days
To evaluate the therapeutic efficacy of LrA combined with OPZ in H. pylori-infected mouse models, results showed that the LrA + OPZ treatment group reduced colony counts of multidrug-resistant H. pylori by 2.6 orders of magnitude, comparable to triple therapy, and had minimal impact on the diversity and composition of mouse gut microbiota.
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0031424
搜索
